Publicaciones en colaboración con investigadores/as de National Taiwan University Hospital (16)

2023

  1. HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 35, pp. 5363-5375

2022

  1. ISARIC-COVID-19 dataset: A Prospective, Standardized, Global Dataset of Patients Hospitalized with COVID-19

    Scientific Data, Vol. 9, Núm. 1

  2. Isatuximab plus atezolizumab in patients with advanced solid tumors: results from a phase I/II, open-label, multicenter study

    ESMO Open, Vol. 7, Núm. 5

2020

  1. Docetaxel with or without Ramucirumab after Platinum-Based Chemotherapy and Checkpoint Inhibitors in Advanced Urothelial Carcinoma: A Pre-Specified Subgroup Analysis from the Phase 3 RANGE Trial

    Bladder Cancer, Vol. 6, Núm. 1, pp. 43-52

  2. Potent cell-cycle inhibition and upregulation of immune response with abemaciclib and anastrozole in Neomonarch, phase II neoadjuvant study in HR+/HER2- Breast cancer

    Clinical Cancer Research, Vol. 26, Núm. 3, pp. 566-580

2019

  1. Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer

    New England Journal of Medicine, Vol. 380, Núm. 20, pp. 1929-1940

2018

  1. Reply to 'the St Gallen international expert consensus on the primary therapy of early breast cancer 2017: Te point of view of an international panel of experts in radiation oncology' by Kirova et al.

    Annals of Oncology

2017

  1. De-escalating and escalating treatments for early-stage breast cancer: The St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017

    Annals of Oncology, Vol. 28, Núm. 8, pp. 1700-1712

  2. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study

    The Lancet, Vol. 389, Núm. 10072, pp. 917-929

2016

  1. A Predictive Model of Mortality in Patients With Bloodstream Infections due to Carbapenemase-Producing Enterobacteriaceae

    Mayo Clinic Proceedings, Vol. 91, Núm. 10, pp. 1362-1371

  2. International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment

    Journal of Clinical Oncology, Vol. 34, Núm. 13, pp. 1544-1557

2014

  1. Angiogenesis inhibitor therapies for advanced renal cell carcinoma: Toxicity and treatment patterns in clinical practice from a global medical chart review

    International Journal of Oncology, Vol. 44, Núm. 1, pp. 5-16

  2. Phase II results of dovitinib (TKI258) in patients with metastatic renal cell cancer

    Clinical Cancer Research, Vol. 20, Núm. 11, pp. 3012-3022

2013

  1. Everolimus is associated with a reduced incidence of cytomegalovirus infection following de novo cardiac transplantation

    Transplant Infectious Disease, Vol. 15, Núm. 2, pp. 150-162

  2. Phase i study of dovitinib (TKI258), an oral FGFR, VEGFR, and PDGFR inhibitor, in advanced or metastatic renal cell carcinoma

    Clinical Cancer Research, Vol. 19, Núm. 5, pp. 1257-1268

2003

  1. Marrow versus peripheral blood for geno-identical allogeneic stem cell transplantation in acute myelocytic leukemia: Influence of dose and stem cell source shows better outcome with rich marrow

    Blood, Vol. 102, Núm. 8, pp. 3043-3051